Hims, Super Bowl and Hers
Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
A still from the 2025 Super Bowl commercial “Sick of the System,” from telehealth company Hims & Hers. © 2024 Fortune Media IP Limited. All Rights Reserved. Use ...
Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...
10h
Zacks.com on MSNHims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to NoteHims & Hers Health, Inc. (HIMS) concluded the recent trading session at $60.30, signifying a +1.88% move from its prior day's close.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results